Elsevier has created a Monkeypox Information Center in response to the declared public health emergency of international concern, with free information in English on the monkeypox virus. The Monkeypox Information Center is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its monkeypox related research that is available on the Monkeypox Information Center - including this research content - immediately available in publicly funded repositories, with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the Monkeypox Information Center remains active.
Short communication

Real-time PCR assay for the detection of tanapox virus and yaba-like disease virus

Pia Zimmermann a, Ingo Thordsen b, Dimitrios Frangoulidis a, Hermann Meyer a,∗

a Bundeswehr Institute of Microbiology, Neuherbergstr. 11, D-80937 Munich, Germany
b Artus GmbH, Koenigstr. 4a, D-22767 Hamburg, Germany

Received 10 April 2005; received in revised form 15 June 2005; accepted 23 June 2005
Available online 28 July 2005

Available online at www.sciencedirect.com
Journal of Virological Methods 130 (2005) 149–153

Abstract

The yatapoxvirus genus contains three members: tanapox virus (TPV), yaba-like disease virus (YLDV) and yaba monkey tumor virus (YMTV) (Büchen-Osmond, 2003). Infections of monkeys and humans with both, TPV and YLDV, have been reported, whereas YMTV has infected so far only non-human primates naturally (Grace and Miranda, 1965). The mode of transmission of yatapoxviruses is not well understood. Biting arthropods are suspected to act as mechanical vectors, however, yatapoxviruses have not been isolated so far from arthropods.

TPV infection is a rare zoonosis and was first observed in the human population in the flood plains of the Tana River in Kenya during two epidemics in 1957 and 1962 (Downie et al., 1971). However, it is believed that TPV is endemic throughout tropical Africa. TPV infection in humans results in an acute febrile illness with one or more localized skin lesions. A mild pre-eruptive fever that lasts 3–4 days is followed by severe headache, backache and lymphadenopathy. Itching occurs at the site where skin lesions ultimately develop. An initially small, pock-like lesion becomes papular and gradually enlarges to reach a maximum diameter of about 15 mm by the end of second week. During the third week, the skin lesion ulcerates and finally heals within 6 weeks, leaving a scar (Downie et al., 1971). Several authors pointed out that TPV-induced lesions in the early stages can be confused easily with smallpox or human monkeypox (Jezek et al., 1985; Downie et al., 1971; Stich et al., 2002; Dhar et al., 2004).

YLDV was first reported during epizootics in 1965 and 1966 in primate centers in the USA with animal handlers presenting identical clinical features as compared to TPV infection (Casey et al., 1967; Crandel et al., 1969; Downie and espana, 1972). The third member of the genus, YMTV, was isolated in 1958 during an outbreak in a colony of captive rhesus monkeys in Yaba, Nigeria. Infected monkeys developed epidermal histocytomas with masses of polygonal...
mononuclear cell infiltrates and the development of a suppurative inflammatory reaction (Niven et al., 1961).

Comparison of YLDV with TPV sequences available in the databases demonstrated a high identity, for instance, the sequences of 12.5 and 10.7 kb from the left and right ends have an identity of >98.6% (Lee et al., 2001). It has been assumed that TPV and YLDV may be different strains of the same virus species. In contrast, comparison of the complete genome sequences of YLDV and YMTV revealed an identity of only about 75% (Brunetti et al., 2003).

Clinical diagnosis of TPV/YLDV infection in humans is based on the appearance of only a few nodular lesions, the absence of pustulation and a benign course. Investigation of scars by electron microscopy cannot differentiate yatapoxviruses from orthopoxviruses (including smallpox and monkeypox virus). Although yatapoxviruses are distinct antigenically from all other poxviruses (Downie et al., 1971), the method of choice is PCR. Two PCR assays for the specific detection of TPV/YLDV have been published (Stich et al., 2002; Dhar et al., 2004).

Increased international travel has led to appearance of TPV infections outside Africa (Stich et al., 2002; Dhar et al., 2004). Given the fact that early stages of this infection can be mistaken for more serious conditions, such as monkeypox, smallpox, tularemia or anthrax, a rapid, unambiguous identification is extremely important to exclude the deliberate use of agents of biological warfare and bioterrorism.

This report describes the development of a rapid PCR assay to detect TPV and YLDV, both of which are human pathogens. The assay uses the closed-tube TaqMan® format that has several advantages over conventional gel-based PCR methods. Most important, the inclusion of a TaqMan® probe confirms the identity of the PCR product, thereby, eliminating time- and labour-intensive post-PCR processing steps prone to cause cross-contamination. Initially, two sets of primers and probes were selected based on the sequence of the PoI L fragment of TPV (Accession number AF153912): the TP-TaqMan® assay, based on a conventional PCR (Stich et al., 2002) with an amplicon size of 333 bp and the IT-TaqMan® assay targeting a 101 bp region. Primers and probes (Table 1) had been selected with Primer Express software (Applied Biosystems, Germany) and the respective sequences did not show any significant homology to other published sequences in the GenBank and EMBL databases by use of the BLAST (www.ncbi.nlm.nih.gov/BLAST) and FASTA (www.ebi.ac.uk/fasta33) algorithms. The following protocol was used for real-time PCR assay: 12.5 µl of TaqMan® Universal PCR Master Mix (Applied Biosystems, Germany), 0.5 µl bovine serum albumin (20 mg/ml), 1 µl (12 µM) of primers IT1/IT1a or TP1/TP1a (Tib-Molbiol, Germany), 0.15 µl probe (30 µM) IT1s or TP1s (Tib-Molbiol, Germany), PCR-graded water to a final volume of 20 µl and 5 µl of template. PCR was performed on a MX3000 (Stratagene, Germany). Real-time PCR involved initial denaturation (95 °C for 10 min), followed by amplification and detection of the DNA target for 45 cycles (95 °C for 15 s and 55 °C for 1 min). R²-values, slopes, efficiencies of amplification (Efficiency = 10(−1/y-intercept) − 1) and y-intercept were determined.

Initial experiments were conducted using DNA of the YLDV strain Davis grown in African green monkey kidney cell line MA 104 at 34 °C. DNA was isolated from 100 µl aliquots by magnetic beads separation using MagNA Pure Compact Nucleic Acid Isolation Kit I on the Magna Pure Compact (Roche, Germany).

A comparison of the two real-time PCR assays using a serial 10-fold dilution of YLDV DNA demonstrated specific amplification for both assays. However, due to lower C_(t) values, a more efficient amplification (average 92.875%) and an almost optimal y-intercept (average 38.95) of the IT-TaqMan® assay led to this assay for further evaluation. It seems that selection of a shorter amplicon (101 bp versus 333 bp of the TP-TaqMan® assay) leads to a higher amplification efficiency.

DNA preparations from five TPV strains and one YMTV strain (kindly provided by J.J. Esposito, Centers for Disease Control, Atlanta, USA), one YLDV strain and scab-derived DNA from a German traveller with a TPV infection (Stich et al., 2002) were examined (Table 2). With the exception of YMTV, all preparations reacted positive in the IT-TaqMan assay (Fig. 1). Lack of amplification of YMTV is in agreement with available YMTV sequence data indicating several mismatches within the primer and probe binding site.

To determine the analytical sensitivity, plasmid pCR 2.1 was generated. This plasmid contains a 465 bp

| Primer/probe | Sequence (Accession number AF153912) | Position | Amplicon size (bp) |
|--------------|--------------------------------------|----------|--------------------|
| TP1s         | AACGATCTGATATGCGATGTAAAATGGT | 377–378  | 100                 |
| TP1a         | AGTTAGTAAAGGAGCAAATG | 1337–1356 | 465                 |
| IT1s         | CAGTGGTACGGATATTCACCTATTCATAA | 1586–1612 | 101                 |
| IT1a         | CGTGTACGGATATTCACCTATTCATAA | 1686–1665 | 101                 |

* Indicates the corresponding nucleotide position of the tanapox virus PoI L fragment (Accession number AF153912).

* According to Stich et al. (2002).
Table 2

Origin and designation of viruses and DNA preparations used in this study

| Virus strain               | Year | Host         | Location  | Amplification IT-TaqMan® assay |
|----------------------------|------|--------------|-----------|--------------------------------|
| Yaba-like disease virus, Davies | Unknown | Monkey      | USA       | Positive                       |
| Tanapox virus, TANVWI-38a  | 1957 | Human        | Kenya     | Positive                       |
| Tanapox virus, TANV#81-I-24a | 1981 | Female, age 11 years | Zaire     | Positive                       |
| Tanapox virus, TANV#81-I-24a | 1980 | Male, age 7 years | Zaire     | Positive                       |
| Yaba monkey tumor virusa  | 1958 | Monkey       | Nigeria   | Negative                       |
| PM/99b                     | 1999 | Male, age 40 years | Germany   | Positive                       |

* DNA was kindly provided by J.J. Esposito, CDC, Atlanta, USA.
* Scab-derived DNA preparation from a patient (Stich et al., 2002).

PCR-amplified TPV sequence generated by using primer pair TP3/TP3a (Table 1) spanning the IT primers and probe. To this end, a standard PCR was carried out in a 50 µl volume containing 5 µl 10× PCR-Mix + MgCl2, 2 µl platinum Taq-polymerase (both Invitrogen, Germany), 3 µl primers (10 µM) TP3/TP3a (Tib-Molbiol, Germany), 1 µl PCR nucleotide Mix (10 mM dNTP each), 32.8 µl PCR-graded water and 5 µl template. Initial denaturation for 5 min at 94 ºC was followed by 35 cycles consisting of a melting step (94 ºC for 1 min), an annealing step (1 min at 52 ºC), an elongation step (72 ºC for 1 min) and a final step (20 min at 72 ºC). A 5 µl aliquot of the PCR product was analysed by gel electrophoresis relative to a size marker (Roth, Germany).

Cloning was carried out using standard procedures and DNA of the resulting plasmid pCR 2.1 was purified and photo metrically quantified. Plasmid DNA was serially diluted in Tris–EDTA buffer (10 mM/1 mM) and tested in eight replicates on 3 independent days with DNA concentrations corresponding to 6.8e + 002, 6.8e + 001, 6.8, 0.68, 0.068 and 0.0068 copies/µl as inputs (Fig. 2). All amplification reactions were run eight-fold in three independent assays. A probit analysis as a model of non-linear regression was done with software SPSS 6.0 and Microcal Origin 4.0. The software determines a continuous 95% confidence interval of the probability of achieving a positive result at any given input DNA concentration within the concentration range of the experiment. The lower limit of detection (LOD) accounts for 8.341 copies/µl with a confidence interval of 95% (Fig. 3).

Due to the rarity of TPV/YLDV infection, the test could only be performed with a scab-derived DNA preparation and with DNA from cell-cultured strains. But, because of the high sensitivity, it is assumed that TPV/YLDV can be diagnosed also from clinical samples taken in earlier stages of infection.

Specificity of the assay was investigated by testing 29 DNA preparations from various rash illness-causing viruses and bacteria including the following: vaccinia virus MV A
and Elstree, cowpox virus Brighton, cat-pox 3, L97 and Norway, camelpox virus VD Mauretania, mousepox virus MP-1, parapoxvirus strain ORP D1701 and avipoxvirus strain HP-1. Varicella Zoster virus, a herpesvirus, causing a similar clinical entity was tested as well as bacterial agents: Bacillus anthracis, Brucella abortus and canis, Burkholderia mallei, pseudomallei and cepacia, Francisella tularensis, Pseudomonas aeruginosa and putida, Staphylococcus aureus and epidermidis, Stenotrophomonas maltophilia, Vibrio parahaemolyticus, Yersinia pseudotuberculosis and pestis. However, no amplification was obtained with any of the preparations tested.

The use of this assay for examining clinical specimens was investigated using 40 DNA preparations from vesicles or crusts of human cases of suspected monkeypox (kindly provided by M. Tamfum, Kinshasa, Democratic Republic of Congo). Of these samples, eight had been confirmed previously as positive for monkeypox virus, while 22 were positive for Varicella Zoster virus (unpublished results). However, none of these samples was positive for TPV/YLDV.

In summary, a highly sensitive and specific TaqMan® assay was developed for the detection of human-pathogenic yatapoxviruses TPV and YLDV. Using this method, it is possible to obtain a reliable laboratory diagnosis within several hours after receipt of specimens. From the public health point of view, it is important to exclude infections which in the early stages might mimic infections caused by a possible bioterrorism agent and therefore pose serious public health consequences. This sensitive and specific test complements nicely the arsenal of existing methods used to discriminate more serious entities such as smallpox, monkeypox, tularemia and anthrax.

Fig. 3. Predicted proportion of positive amplification results versus the input concentration of purified plasmid DNA as determined by probit regression analysis. The concentration at which 95% of results are expected to be positive was calculated to be ca. 8 copies/μl.
Acknowledgements

Technical support provided by D. Wenzel is gratefully acknowledged. DNA of various bacterial species were kindly provided by H. Tomaso, Bundeswehr Institute of Microbiology, Munich, Germany.

References
Brunetti, C.R., Amano, H., Ueda, Y., Qin, J., Miyamura, T., Suzuki, T., Li, X., Barrett, J.W., McFadden, G., 2003. Complete genomic sequence and comparative analysis of the tumorigenic poxvirus yaba monkey tumor virus. J. Virol. 77 (24), 13335–13347.

Büchen-Osmond, C., 2003 (Ed.). ICTVdB—The Universal Virus Database, Version 3. ICTVdB Management, Columbia University, NY, USA.

Casey, H.W., Woodruff, J.M., Butcher, W.L., 1967. Electron microscopy of a benign epidermal disease of rhesus monkeys. Am. J. Pathol. 51, 431–446.

Crandel, R.A., Casey, H.W., Brunlow, W.B., 1969. Studies of a newly recognized poxvirus of monkeys. J. Infect. Dis. 119, 80–88.

Dhar, A.D., Werchniak, A.E., Li, Y., Brennick, J.B., Goldsmith, C.S., Kline, R., Damon, J., Klaus, S.N., 2004. Tanapox infection in a college student. N. Engl. J. Med. 350 (4), 361–366.

Downie, A.W., Taylor-Robinson, C.H., Caunt, A.E., Nelson, G.S., Manson-Bahr, P.E., Mathers, C., 1971. A new disease caused by a pox virus. Br. Med. J. 1 (745), 363–368.

Downie, A.W., Espina, C., 1972. Comparison of tanapox virus and yaba-like viruses causing epidemic disease in monkeys. J. Hyg. (Lond.) 70 (1), 23–32.

Grace, J.T., Mirand, E.A., 1965. Yaba virus infection in humans. Exp. Med. Surg. 23 (2), 213–216.

Jejez, Z., Arino, I., Szczepanski, M., Pulska, K.M., Kallou, R., Nakano, J.H., 1985. Human tanapox in Zaire: clinical and epidemiological observations on cases confirmed by laboratory studies. Bull. WHO 63, 1027–1035.

Lee, H.J., Essai, K., Smith, G.L., 2001. The genome sequence of the poxvirus yaba-like disease virus, a yatapoxvirus. Virology 281 (2), 170–192.

Niven, J.S.F., Armstrong, J.A., Andrewes, C.H., Pereira, H.G., Valentine, R.C., 1961. Subcutaneous "growth" in monkeys produced by a poxvirus. J. Pathol. Bacteriol. 81, 1–14.

Stich, A., Meyer, H., Kehley, B., Fleischer, K., 2002. Tanapox: first report in a European traveller and identification by PCR. Trans. R. Soc. Trop. Med. Hyg. 96 (2), 178–179.